Skip to content

Journal · Ophthalmology · Updated 22 November 2026

Ophthalmology and Therapy

Read Ophthalmology and Therapy articles on DeepDyve. No university library needed.

Ophthalmology and Therapy covers the diagnosis and treatment of eye disease, from myopia in children and dry eye to thyroid eye disease and AI screening for diabetic retinopathy. Springer Nature publishes it, and it has published since 2012. A DeepDyve subscription lets you read it in full, alongside millions of articles from other journals licensed from publishers including Springer Nature.

Then $59 a month or $499 a year. A credit card is required; cancel during the trial and you won’t be charged. You read articles online; PDFs are sold separately.

Personal plans aren’t for business use. Reading for work? See Enterprise.

Cover of Ophthalmology and Therapy
Journal cover

Ophthalmology and Therapy at a glance

Full title
Ophthalmology and Therapy
Abbreviation (NLM)
Ophthalmol Ther
Publisher
Springer Nature
Print ISSN
2193-8245
Online ISSN (eISSN)
2193-6528
First published
2012
Access model
Open access since 2012

Ways to access Ophthalmology and Therapy

All of the articles Ophthalmology and Therapy published from January 1 to November 20, 2026 are open access and free to read. For older articles, look for the authors’ manuscript, check a library, or read them on DeepDyve.

  1. Open access articles. 100% of Ophthalmology and Therapy articles published from January 1 to November 20, 2026 carry a Creative Commons license, per Crossref, and are free to read. They’re marked “Open access” below.
  2. The authors’ accepted manuscript. For subscription articles, Springer Nature lets authors post their accepted manuscript on their own website as soon as it’s accepted, and in a repository such as PubMed Central 12 months after publication.
  3. Ask the authors. Authors can also share a free, read-only link to their published article through Springer Nature’s SharedIt, so it’s worth asking the authors directly.
  4. NIH-funded research. For papers accepted on or after July 1, 2025, the US National Institutes of Health requires the accepted manuscript in PubMed Central, free with no embargo from the official publication date.
  5. A library. Your university, hospital or public library may subscribe to Ophthalmology and Therapy. Check its journal list and whether it offers remote access.
  6. DeepDyve. Read Ophthalmology and Therapy articles online for $59 a month or $499 a year after a free first month. Articles marked LitStream below are in DeepDyve’s LitStream collection, which a subscription lets you read online. PDFs are sold separately, and availability varies by article.

Sources: Springer Nature self-archiving policy; NIH Public Access Policy; open access share from Crossref license data.

Impact factor and metrics

Ophthalmology and Therapy’s 2025 Journal Impact Factor is 4.2, and its 5-year Impact Factor is 4.0.

4.2

Journal Impact Factor (2025)

4.0

5-year Impact Factor (2025)

2 days

Median time to first decision

1.2M

Downloads (2025)

Source: journal metrics on the Ophthalmology and Therapy homepage (Springer Nature), checked November 22, 2026. Impact Factor from Clarivate Journal Citation Reports.

Recent Ophthalmology and Therapy research worth reading

Published January to March 2026. Summaries describe what the authors report.

  1. Open accessDiabetic retinopathy · Artificial intelligence

    Artificial Intelligence-Based Medical Devices for Diabetic Retinopathy Screening in the European Union

    Reviewing 13 CE-certified AI systems for diabetic retinopathy screening in the European Union, the authors report that most analyze fundus images with deep learning, but that evidence varies widely, especially for sight-threatening disease and real-world implementation.

    Grzybowski et al. · Ophthalmology and Therapy, published online January 30, 2026 · DOI 10.1007/s40123-026-01322-3

  2. Open accessThyroid eye disease · Clinical guidelines

    Management of Thyroid Eye Disease: A Comparison Between Three Recent Clinical Guidelines

    The authors compare three recent thyroid eye disease guidelines, from European, Chinese and American and European thyroid societies, across 11 dimensions from diagnosis to treatment, finding broad consensus but important differences that could affect patient care.

    Lei et al. · Ophthalmology and Therapy, published online February 16, 2026 · DOI 10.1007/s40123-026-01326-z

  3. Open accessMyopia · Children

    STudy of Atropine to Reduce (STAR) Myopia Progression in Children: 24-Month Results of a Randomized, Double-Masked, Vehicle-Controlled Trial of Atropine Sulfate 0.01% and 0.03%

    In a phase 3 trial of 847 children in Europe and the USA, the authors report that atropine sulfate 0.01% and 0.03% slowed myopia progression over 24 months, to − 0.31 and − 0.32 D/year versus − 0.44 D/year with vehicle.

    Korenfeld et al. · Ophthalmology and Therapy, published online March 23, 2026 · DOI 10.1007/s40123-026-01341-0

  4. Open accessMyopia · Mood disorders

    The Light–Eye–Brain Axis: Neurobiological Links Between Mood Disorders and Myopia—A Narrative Review

    The authors propose a light-eye-brain axis linking mood disorders and myopia, arguing that mood disturbances may speed myopia through light exposure, neurotransmitter and stress hormone changes, while high myopia may raise vulnerability to anxiety or depression.

    Li et al. · Ophthalmology and Therapy, published online February 3, 2026 · DOI 10.1007/s40123-026-01315-2

  5. Open accessDry eye disease · Air pollution

    Environmental Drivers of Dry Eye Disease: A Narrative Review of Pollutants, Climate, and Indoor Exposures with Practice Recommendations

    The authors review how climate, air pollution and indoor exposures affect dry eye disease, noting higher risk in dense cities, industrial zones and dry climates, and recommend screening, environmental risk assessment, counseling and personalized management.

    Duarte et al. · Ophthalmology and Therapy, published online January 8, 2026 · DOI 10.1007/s40123-025-01297-7

See every Ophthalmology and Therapy article on DeepDyve

Questions about Ophthalmology and Therapy

How can I read Ophthalmology and Therapy articles without a subscription?

100% of Ophthalmology and Therapy articles published from January 1 to November 20, 2026 are open access and free to read. For subscription articles, Springer Nature lets authors post their accepted manuscript on their own website as soon as it’s accepted, and in a repository such as PubMed Central 12 months after publication. Your library may also subscribe. DeepDyve lets you read Ophthalmology and Therapy articles online for $59 a month or $499 a year after a free first month.

What is the abbreviation for Ophthalmology and Therapy?

Ophthalmology and Therapy’s NLM (PubMed) abbreviation is Ophthalmol Ther.

What is the ISSN of Ophthalmology and Therapy?

The print ISSN is 2193-8245 and the online ISSN is 2193-6528.

What is the impact factor of Ophthalmology and Therapy?

Ophthalmology and Therapy’s Journal Impact Factor is 4.2 (2025), and its 5-year Impact Factor is 4.0, according to Springer Nature’s published metrics.

Is Ophthalmology and Therapy open access?

Yes. Ophthalmology and Therapy has published open access since 2012: 227 of the 227 articles it published from January 1 to November 20, 2026 carry a Creative Commons license, per Crossref.

Ophthalmology and Therapy articles on DeepDyve are licensed from Springer Nature. Journal facts as of 22 November 2026.

Start reading Ophthalmology and Therapy today

One month free, then less than $2 a day. Ophthalmology and Therapy, plus millions of articles from thousands of journals.

Start free month

Like this: